Adagene Presents Interim Results Reinforcing Best-in-Class P

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...

Related Keywords

San Francisco , California , United States , Suzhou , Jiangsu , China , Japan , Australia , Singapore , American , Daneng Li , Heinz Josef Lenz , Professor Department Of Medical Oncology Therapeutics Research , Translational Science Program , Merck Co Inc , Linkedin , Clinical Research , Merck Sharp Dohme , Dynamic Precision Library , Nasdaq , Norris Comprehensive Cancer Center , Adagene Inc , Twitter , European Union , Exchange Commission , American Society Of Clinical Oncology , City Of Hope Comprehensive Cancer Center , American Society , Clinical Oncology , Cancers Symposium , Associate Professor Department , Medical Oncology , Therapeutics Research , Hope Comprehensive Cancer , Associate Director , Comprehensive Cancer Center , Merck Sharp ,